Manjarrez EA, Campos CJC

Language: Spanish
References: 11
Page: 262-265
PDF size: 86.76 Kb.

ABSTRACT

Introduction: Pemphigus vulgaris is an autoimmune disease in which circulating antibodies are found and fixed tissues against keratinocytes. The course of the disease is progressive and can cause from septic shock to death. Conventional treatment is with steroids, immunosuppressants (azathioprine, cyclophosphamide) and immunomodulators (dapsone, gold). Immunoglobulin can be used as part of the treatment sometimes.
Case report: This is the case of a female of 51-year-old, with type 2 diabetes, whith sings and symptom of influenza-like illness, she was treated with cephalexin and nimesulide, at 12 hrs of treatment presented macular erythema, located in the limbs and chest, associated to itching, vesicles and blisters. She presented septic shock secondary to community-acquired pneumonia with multiple organ failure and require support in The intensive care unit. She Was treated with hydrocortisone, chlorpheniramine, antibiotics and oseltamivir because she acomplished operational criteria of influenza. She Was treated with immunoglobulin because of increase in skin lesions extension. After immunoglobulin treatment the skin lesions decreased. The skin's biopsy reported pemphigus vulgaris.
Discussion: Immunoglobulin is an alternative in the treatment of pemphigus vulgaris whose disease can not be controlled with steroids.
Conclusion: Immunoglobulin is useful in drug-induced pemphigus.

REFERENCES

1. Zambrano MT. Pénfigo. Dermatología Rev Mex 2004;48:249-73.

2. Magaña JF, Nellen H, Halabe J. Pénfigo. Med Int Mex 2001;17(5):230-5.

3. Murrell DF, Dick S, Ahmed AR, et al. Concensus statement on definitions of disease, end points, and therapeuticsresponse for pemphigus. J Am Acad Dermatol 2008;58(6):1043-1046.

4. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-937.

5. Bystryn JC, Rudolph JL. IVIg treatment of pemphigus: How in Works & How to use it. J Invest Dermatol 2005;125:1093-1093.

6. Watter D, Denis M, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin theraphy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005;80(1):41-47.

7. Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002;138:1158-1162.

8. Nieves A, Ochoa J, Martínez V, et al. Tratamiento con dosis altas de inmunoglobulina intravenosa en un caso de pénfigo vulgar complicado. Rev Alergia Mex 2005;52(1):39-41.

9. Segura S, Iranzo P, Martínez de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007;56(6):960-967.

10. Amagai m, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009;60(4):595-602.

11. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998;134:80-86.